Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $9.8 million.

  • Iovance Biotherapeutics' Prepaid Assets changed N/A to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year change of. This contributed to the annual value of $12.4 million for FY2024, which is 2910.41% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Prepaid Assets of $9.8 million as of Q3 2025.
  • Iovance Biotherapeutics' Prepaid Assets' 5-year high stood at $17.5 million during Q4 2023, with a 5-year trough of $9.8 million in Q3 2025.
  • For the 3-year period, Iovance Biotherapeutics' Prepaid Assets averaged around $12.9 million, with its median value being $12.0 million (2023).
  • In the last 5 years, Iovance Biotherapeutics' Prepaid Assets tumbled by 2910.41% in 2024 and then surged by 3836.51% in 2025.
  • Iovance Biotherapeutics' Prepaid Assets (Quarter) stood at $17.5 million in 2023, then decreased by 29.1% to $12.4 million in 2024, then decreased by 20.68% to $9.8 million in 2025.
  • Its last three reported values are $9.8 million in Q3 2025, $11.5 million for Q2 2025, and $15.9 million during Q1 2025.